InvestorsHub Logo
Followers 7
Posts 354
Boards Moderated 0
Alias Born 08/12/2019

Re: HDGabor post# 250912

Monday, 03/09/2020 3:38:00 AM

Monday, March 09, 2020 3:38:00 AM

Post# of 429287
Why do we think double digits = 20%, why not 50%

If the HLS deal is in the 20s it is the worst deal I ever heard of, with a drug that only needs selling , no trials or development to be run by HLS.

I would expect around 50% of net sales, that goes for EU as well, and with a very healthy upfront payment. If less than 50% we need big sales milestone along the way. But my money is on EU BO.

Remember they are not buying a biotech with a promising un-approved drug and a lot of trial costs and risks. They are investing in an approved drug. If their net profit (EBIT) on Vascepa sales is >= 30% its a home run for the buyer.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News